Instruction for use: Immunomax

Dosage form: Lyophilizate for the preparation of a solution for intramuscular injection

ATX

L03AX Other immunostimulants

Pharmacological group:

Other immunomodulators

The nosological classification (ICD-10)

A49 Bacterial infection of unspecified site: Bacterial infection; Infectious diseases

A49.3 Mycoplasma infection, unspecified: Mycoplasma infection; Urogenital mycoplasmosis; Pulmonary infection caused by mycoplasma; Mycoplasma infections; Mycoplasmosis; Genitourinary infection caused by mycoplasma; Mycoplasma meningoencephalitis

A70-A74 Other diseases caused by chlamydiae

B00 Infections caused by the herpes simplex virus [herpes simplex]: Herpes simplex; Herpes virus; Herpes simplex virus; Herpes simplex virus type I and II; HSV; Herpes; Herpes simplex / herpes simplex /; Herpes lips; Herpes simplex; Herpes in patients with immunodeficiency; Labial herpes; Acute herpetic disease of the mucous membranes; Herpes simplex; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Recurrent herpes; Urogenital herpetic infection; Chronic recurrent herpesvirus infection; Herpes-viral infections of various localizations

B07 Viral Warts: Warts; Human Wart Virus; Vulgar warts; Flat wart; Flat and vulgar wart in children; Plantar wart; Common wart; Common plantar wart; Skin Papillomas

B34 Viral infection of unspecified site: Viral respiratory tract infections; Infections viral; Viral infection; Viral infections

D84.9 Unspecified Immunodeficiency: Pneumonia in immunodeficient states; Autoimmune disease; Autoimmune diseases; Severe immunodeficiency; immune deficiency; Immunodeficiency; immunodeficiency diseases; Immunodeficiency states due to surgery; Immunotherapy for cancer; Immunomodulation; Infections in patients with weakened immune systems; Correction of immune deficiency; Correction of immunodeficiencies; Correction of a weakened immune system; Correction of a weakened immunity in immunodeficient states; Violation of immunity; Violation of the immune status; Immune System Disorders; Primary immunodeficiency; Maintaining immunity; Lowering the body's defenses; Lowering the immunity; Lowering the immunity of colds and infectious diseases; The decrease of the immune status; Lowered resistance to infections; Lowered resistance to infections and colds; Lowered resistance; Immunosuppression; Predisposition to colds; acquired immune deficiencies; Radiation immunodeficiency; The development of immunodeficiency; Immune dysfunction syndrome; immunodeficiency syndrome; primary immunodeficiency syndrome; Reducing the body's defenses; Immunosuppression; Reduced immune defense; Reducing local immunity; Reducing the total body resistance; The decrease in cell-mediated immunity; Reduced resistance to infections in children; Reducing the body's resistance; Reduced resistance; reduced immunity; Status immunodeficiency; Stimulation of the processes of nonspecific immunity; Heavy selective secondary immunodeficiency; immunity Oppression; Primary immunodeficiency

Composition and release form

Powder lyophilized for the preparation of injection solution for intravenous injection 1 fl.

Acid peptidoglycan with a molecular weight of 1000-40000 kD 100 U; 200 units

In a vial with a solvent in an ampoule, a syringe and a napkin; In a pack of cardboard 1 or 3 bottles or in a box of 30 bottles.

Description of dosage form

Lyophilized powder of white color.

Characteristic

Acid peptidoglycan with a molecular mass of 1000-40000 kD.

Pharmachologic effect

Mode of action - antiviral, immunomodulating.

Strengthens immune defense against viral and bacterial infections.

Pharmacodynamics

Immunopharmacological mechanisms of action of the drug consist in the fact that it activates the following links of immune defense:

- NK cells, which 2-3 h after exposure to the drug intensively express the activation molecules of CD69; The cytolytic activity of NK cells increases 3-fold;

- circulating monocytes 2-4 h after activation with the drug begin to secrete cytokines: interleukin-8, interleukin-1-beta and tumor necrosis factor alpha;

- neutrophilic granulocytes are activated due to the activation of monocytes, the drug does not directly affect neutrophilic granulocytes; Secreted by monocytes, interleukin-8 induces activation of neutrophilic granulocytes, which clearly manifests itself 24 hours after exposure;

- tissue macrophages, which is manifested in a change in the morphology of these cells, enhance the production of bactericidal substances, change the activity of 5'-nucleotidase;

- the formation of antibodies against foreign antigens, soluble and corpuscular.

Strengthens protection against infections caused by viruses (human papilloma virus, herpes simplex virus, parvovirus, carnivore plague virus and others) or bacteria (E. coli, Salmonella, Staphylococcus, Chlamydia, Mycoplasma, ureaplasma and others). This effect is manifested in adults and newborns when the drug is administered in various ways: in / m, intravenously, intraperitoneally, orally.

Pharmacokinetics

It has not been studied in connection with the peptidoglycan nature of the drug and very small acting doses.

Indication of the Immunomax

Correction of weakened immunity; Treatment of pathological conditions (condylomata, warts, dysplasia and others) caused by the human papillomavirus; Treatment of infections caused by the herpes simplex virus, chlamydia, mycoplasma, ureaplasma, other bacteria and viruses.

Contraindications

Hypersensitivity to the drug; Children under 12 years.

Application in pregnancy and breastfeeding

There is no data on the effects of the drug on pregnant women. As with other drugs, should not be used during pregnancy, unless the benefits obtained by the patient do not exceed the possible risk to the fetus. Not recommended for nursing mothers.

Side effects

Not detected.

Interaction

Not described.

Dosing and Administration

IM. The recommended dose for adults and children over 12 years is 100-200 units 1 time per day. Before use, the contents of the ampoule are dissolved in 1 ml of water for injection, injected in / m for 100-200 units, depending on the severity of the disease. The course of treatment - 6 injections in 1, 2, 3, 8, 9, 10 days of treatment.

Treatment of recurrent anogenital warts: course - 6 injections of 200 units are combined with the destruction of warts by one of the most common methods: cryodestruction, electrocoagulation, laser destruction or the appointment of solcoderm. Treatment of infections caused by bacteria or viruses: a course of 6 injections of 100-200 units. Correction of weakened immunity: a course of 3-6 injections of 100-200 units.

Manufacturer

OOO IMMAFARMA, Russia.

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Immunomax

At a temperature of 4-8 ° C.

Keep out of the reach of children.

Shelf life of the drug Immunomax

2 years.

Do not use after the expiry date printed on the package.